세계의 순환종양세포(CTC) 시장(2023-2030년)

Title: Global Circulating Tumor Cells Market Size, Share & Trends Analysis Report by Technology (CTC Detection and Enrichment Methods, CTC Direct Detection Methods, and CTC Analysis), by Product (Kits and Reagents, Blood Collection Tubes and Devices), and by End Users (Hospitals and Clinics, Research and Academic Institutes and Diagnostic Centers),Forecast Period (2023-2030).

Global circulating tumor cells market is anticipated to grow at a CAGR of 12.5% during the Forecast Period (2023-2030). Circulating tumor cells (CTC) provide a blood biomarker for early carcinogenesis, cancer progression, and treatment effectiveness. The growing adoption of CTC assays has attracted intense interest as a biomarker that may assist in disease management and is acting as a key supporting factor for the growth of the market globally. Various test offers physicians the ability to serially monitor their patients' response to treatment, especially for circulating tumor monitoring assay, using a simple blood draw, and using those insights to make informed decisions for future care. Hence, the market players are also focusing on introducing circulating tumor cell-based monitoring assays that further bolster market growth. For instance, in January 2023, Foundation Medicine, Inc., in molecular profiling for cancer, and Natera, Inc., in cell-free DNA testing, launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

Segmental Outlook

The global circulating tumor cells market is segmented on the technology, product, and end users. Based on the technology, the market is sub-segmented into CTC detection and enrichment methods, CTC direct detection methods, and CTC analysis. Based on the product, the market is sub-segmented into kits and reagents, blood collection tubes, and devices. Further, based on end users, the market is sub-segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Among the technology, the CTC detection and enrichment methods sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of nanotechnology, microfluidic chips modified with functionalized nanomaterials which are widely used in the enrichment and detection of CTCs.

The Kits and Reagents Sub-Segment is Anticipated to Hold a Considerable Share of the Global Circulating Tumor Cells Market

Among the products, the kits and reagents sub-segment is expected to hold a considerable share of the global circulating tumor cells (CTC) market. The segmental growth is attributed to the growing influence of the non-invasive culture medium kit and reagents in the detection of cancer. Tumor cells derived from individual patients - hold promise in helping improve clinical trial success rates by enabling researchers to better model disease and predict patient response to therapeutics in vitro. Companies' new off-the-shelf, modular tumoroid culture medium kit is designed to make complex cancer models more accessible to researchers. For instance, in June 2023, Thermo Fisher Scientific, in serving science, launched the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications.

Regional Outlook

The global circulating tumor cells market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a considerable CAGR owing to the adoption of effective diagnostic tools such as CTC-based tests and non-invasive methods for the diagnosis of circulating tumors. The key market players include AnchorDx, Burning Rock Biotech Ltd., Exact Sciences Corp., Guardant Health, Otsuka Pharmaceutical Co., Ltd., and others.

The North America Region is Expected to Dominant in the Global Circulating tumor cells Market

Among all regions, the North American region is anticipated to have the largest market share over the forecast period. Regional growth is attributed to the presence of a large patient population, strong presence of key players, ease of drug availability, well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, a higher number of researches, development, & innovation activities and higher adoption of advanced circulating tumor cells (CTC) technology. Regional growth is attributed to an increase in cancer patients.

According to the American Cancer Society (ACS), in January 2023, About 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 mortality from lung cancer (67,160 in men and 59,910 in women). The rise in investment by key market players in the region, along with the rise in the adoption of various strategies by the key players is anticipated to increase opportunities in the market. The key market players include Advanced Cell Diagnostics, Bio-Rad Laboratories, Inc., Epic Sciences, Ikonisys Inc., Illumina, Inc., and others.

Market Players Outlook

The major companies serving the circulating tumor cells market include: Bio-Rad Laboratories, Inc., Illumina, Inc., Johnson & Johnson, QIAGEN N.V., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, Epic Sciences, Inc. and Predicine, Inc. entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine's ctDNA-based testing and Epic's CTC-based testing. Epic's CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR, and other phenotypic tests.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global circulating tumor cells market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Bio-Rad Laboratories, Inc.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. QIAGEN N.V.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Thermo Fisher Scientific Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Johnson & Johnson Service Inc.
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Illumina, Inc.
  • 3.6.1. Overview
  • 3.6.2. Financial Analysis
  • 3.6.3. SWOT Analysis
  • 3.6.4. Recent Developments
• 3.7. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Circulating Tumor Cells Market by Technology
  • 4.1.1. CTC Detection and Enrichment Methods
  • 4.1.2. CTC Direct Detection Methods
  • 4.1.3. CTC Analysis
• 4.2. Global Circulating Tumor Cells Market by Product
  • 4.2.1. Kits and Reagents
  • 4.2.2. Blood Collection Tubes
  • 4.2.3. Devices
• 4.3. Global Circulating Tumor Cells Market by End Users
  • 4.3.1. Hospitals and Clinics
  • 4.3.2. Diagnostic Centers
  • 4.3.3. Research and Academic Institutes

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Advanced Cell Diagnostics
• 6.2. Akadeum Life Sciences, Inc.
• 6.3. BIOCEPT, Inc.
• 6.4. BioFluidica, Inc.
• 6.5. Biolidics Ltd.
• 6.6. Creativ MicroTech, Inc.
• 6.7. Epic Sciences
• 6.8. Fluxion Biosciences, Inc.
• 6.9. Ikonisys Inc.
• 6.10. LineaRx, Inc. (Applied DNA Sciences)
• 6.11. LungLife AI, Inc.
• 6.12. Menarini Silicon Biosystems
• 6.13. Miltenyi Biotec
• 6.14. OncoDiscover
• 6.15. Precision Medicine Group, LLC.
• 6.16. Sysmex Corporation
• 6.17. ScreenCell
• 6.18. STEMCELL Technologies, Inc.